Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: A pilot study

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1118-1122

  Rueda, A ^a   Alba, E ^a   Ribelles, N ^a   Sevilla, I ^a   Ruiz, I ^a   Miramon J ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; MALE; PRIORITY JOURNAL;

EID: 0031056425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1118     Document Type: Article

References (37)

1. Urba WJ, Longo DL: Hodgkin's disease. N Engl J Med 326:678-687, 1992
2. Hoppe RT: Radiation therapy in the management of Hodgkin's disease. Semin Oncol 17:704-715, 1990
3. A supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6:1576-1583, 1988
4. Bookman MA, Longo DL: Concomitant illness in patients treated for Hodgkin's disease. Cancer Treat Rev 13:77-111, 1986
5. Henry-Amar M, Joly F: Late complications after Hodgkin's disease. Ann Oncol 7:S115-S126, 1996 (suppl 4)
6. Cosset JM, Henry-Amar M, Pellae-Cosset B, et al: Pericarditis and myocardial infarctions after Hodgkin's disease therapy at the Institut Gustave Roussy. Int J Radiat Oncol Biol Phys 21:447-449, 1991
7. Morgan GW, Freeman AP, Maleau RG, et al: Late cardiac, thyroid and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease, Int J Radial Oncol Biol Phys 11:1925-1931, 1985
8. Longo DL, Glatstein E, Duffey PL, et al: Radiation therapy versus combination chemotherapy in the treatment of early stage Hodgkin's disease: Seven-year results of a prospective randomized trial. J Clin Oncol 9:906-917, 1991
9. O'Dwyer PJ, Wiernik PH, Stewart MB, et al: Treatment of early stage Hodgkin's disease: A randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone, in Cavalli F, Bonadonna G, Rozencweig M (eds): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Developments in Oncology, vol 32. Boston, MA. Martinus Nijhoff, 1985, pp 329-336
10. Longo DL: Chemotherapy alone in the treatment of patients with early stage Hodgkin's disease. Ann Oncol 7:S85-S89, 1996 (suppl 4)
11. Blayney DW, Longo DL, Young RC, et al: Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 316:710-714, 1987
12. Henry-Amar M, Dietrich PY: Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am 7:369-387, 1993
13. Valagussa P, Bonadonna G: Hodgkin's disease and second malignancies. Ann Oncol 4:94-95, 1993 (editorial)
14. Pedersen-Bjergaard J, Specht J, Larsen SO, et al: Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Lancet 2:83-88, 1987
15. Tubiana M, Henry-Amar M, Carde P, et al: Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease: The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 73:47-56, 1989
16. Carde P, Hagenbeek A, Hayat M, et al: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258-2272, 1993
17. Pavlovsky S, Maschio M, Santarelli MJ, et al: Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 80:1466-1473, 1988
18. Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM: Gonadal function following chemotherapy for Hodgkin's disease: A comparative study of MVPP and a seven-drug Hybrid regimen. J Clin Oncol 13:134-139, 1995
19. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
20. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
21. Valagussa P, Santoro A, Fossati-Bellani F, et al: Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood 59:488-494, 1982
22. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
23. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Hughes DB, Smith AR, Hoppe RT, et al: Treatment planning for Hodgkin's disease: a patterns of care study. Int J Radiat Oncol Biol Phys 33:519-524, 1995
26. Viviani S, Santoro A, Ragni G, et al: Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP vs. ABVD. Eur J Cancer Clin Oncol 21:601-605, 1985
27. Desablens B, Tourani JM, Casassus P, et al: Traitement des formes localisées de la maladie de Hodgkin par 3 cures de chimiothérapie (ABVD-MP) associées à une radiothérapie focale élargie et lumbo-splénique prophylactique. Protocole POF 81/12. Presse Med 18:1917-1927, 1989
28. Canellos GP: Current strategies for early Hodgkin's disease. Ann Oncol 7:S91-S93, 1996 (suppl 4)
29. Blum RH, Carter SK, Agre K: A clinical review of bleomycin - A new antineoplastic agent. Cancer 31:903-914, 1973
30. Comis RL: Bleomycin pulmonary toxicity: Current status and future directions. Semin Oncol 19:64-70, 1992 (suppl 5)
31. Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 14:1421-1430, 1996
32. Einhorn L, Williams S, Loehrer P, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
33. Hirsch A, Vander Els N, Straus D, et al: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14:1297-1305, 1996
34. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
35. Bonfante V, Santoro A, Viviani S, et al: ABVD in the treatment of Hodgkin's disease. Semin Oncol 19:38-45, 1992 (suppl 5)
36. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, et al: Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 10:1444-1451, 1992
37. Shephard L, Ottaway J, Myles J, et al: Therapy-related leukemia associated with high-dose 4-epi-doxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer. J Clin Oncol 12:2514-2515, 1994